Literature DB >> 11480849

Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden.

O Nived1, A Bengtsson, A Jönsen, G Sturfelt, H Olsson.   

Abstract

The objective of this study was to identify all malignancies in an inception cohort of SLE patients in southern Sweden and compare with the observed frequencies and spectrum of malignancies in the general population. All adult incidence cases of SLE in a defined population during the period 1981-1996 were retrieved from a prospective database and the cases were followed to endpoint or through 1998. The SLE cohort registry was aggregated with the National Cancer Registry to identify all malignancies by date, type and outcome. Standardized morbidity rates (SMR) were calculated based on the sex- and age-matched general population of the region. Sixteen malignancies occurred in 13 patients out of a total of 116 SLE patients observed for 1086 patient-years. The SMR for all cancers detected was 2.24 (confidence interval 0.6-5.7) for males and 1.02 (confidence interval 0.4-2.1) for females and thus indicative of no general increase in malignancies. However, the SMR for non-Hodgkin lymphoma was 11.63 (confidence interval 1.4-42.0), for pulmonary cancer 5.55 (confidence interval 0.7-20.1) and prostatic cancer 6.41 (confidence interval 1.3-18.7) all significantly increased. The increase in prostatic carcinoma disappeared when only cases occurring after a latency period of 3y after SLE diagnosis were included. In this comprehensive inception cohort of SLE no increase in relative risk of malignancy overall was found, but the frequencies of non-Hodgkin lymphoma and pulmonary cancer were increased, possibly also the frequency of prostatic carcinoma.

Entities:  

Mesh:

Year:  2001        PMID: 11480849     DOI: 10.1191/096120301678416079

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  19 in total

Review 1.  Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review.

Authors:  Iuri Usêda Santana; Alline do Nascimento Gomes; Leomar D'Cirqueira Lyrio; Maria Fernanda Rios Grassi; Mittermayer Barreto Santiago
Journal:  Clin Rheumatol       Date:  2010-10-31       Impact factor: 2.980

Review 2.  Prostate cancer in systemic lupus erythematosus.

Authors:  S Bernatsky; R Ramsey-Goldman; C Gordon; A E Clarke
Journal:  Int J Cancer       Date:  2011-03-29       Impact factor: 7.396

Review 3.  A review on SLE and malignancy.

Authors:  May Y Choi; Kelsey Flood; Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Best Pract Res Clin Rheumatol       Date:  2017-11-10       Impact factor: 4.098

4.  No association between the risk of breast cancer and systemic lupus erythematosus: evidence from a meta-analysis.

Authors:  Zahra Rezaieyazdi; Samira Tabaei; Yalda Ravanshad; Javad Akhtari; Hassan Mehrad-Majd
Journal:  Clin Rheumatol       Date:  2018-01-02       Impact factor: 2.980

5.  Malignancies associated with systemic lupus erythematosus in Taiwan: a nationwide population-based cohort study.

Authors:  Ji-An Liang; Li-Min Sun; Jun-Jun Yeh; Wan-Yu Lin; Shih-Ni Chang; Hung-Chang Sung; Chia-Hung Kao
Journal:  Rheumatol Int       Date:  2010-12-31       Impact factor: 2.631

Review 6.  A systematic review of the epidemiological literature on the risk of urological cancers in systemic lupus erythematosus.

Authors:  Hou-Bao Huang; Shu-Chuan Jiang; Jie Han; Qing-Shui Cheng; Chang-Bin Dong; Cai-Ming Pan
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-14       Impact factor: 4.553

Review 7.  Malignancy and systemic lupus erythematosus.

Authors:  Sasha Bernatsky; Ann Clarke; Rosalind Ramsey-Goldman
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

8.  Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California.

Authors:  Arti Parikh-Patel; Richard H White; Mark Allen; Rosemary Cress
Journal:  Cancer Causes Control       Date:  2008-04-02       Impact factor: 2.506

9.  IgG deposits can be detected in cell nuclei of patients with both lupus erythematosus and malignancy.

Authors:  Ingrid Böhm
Journal:  Clin Rheumatol       Date:  2007-03-16       Impact factor: 2.980

10.  A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study.

Authors:  B Löfström; C Backlin; C Sundström; A Ekbom; I E Lundberg
Journal:  Ann Rheum Dis       Date:  2007-05-21       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.